Metraipolis › archive › dc_f4eab4c323c0

Feasibility of the inhibitor development for cancer: A systematic approach for drug design — Europe PMC PMID:39173044

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/39173044
DOI
10.1371/journal.pone.0306632
License (as archived)
solo-consultazione
Archived
2026-10-08T04:37:00.944Z
SHA-256 of the archived text
a6a6dc5f9abdc59993e0f9162d36edf2f54b82543649bd77585ab6cb508aee2f
Stable URL of this page
https://metraipolis.com/documento/dc_f4eab4c323c0

How to cite

Feasibility of the inhibitor development for cancer: A systematic approach for drug design — Europe PMC PMID:39173044 — Europe PMC (en), https://europepmc.org/article/MED/39173044 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f4eab4c323c0 (Metraipolis archive dc_f4eab4c323c0, sha256 a6a6dc5f9abdc59993e0f9162d36edf2f54b82543649bd77585ab6cb508aee2f)
BibTeX
@misc{dcf4eab4c323c0,
  title = {Feasibility of the inhibitor development for cancer: A systematic approach for drug design — Europe PMC PMID:39173044},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/39173044},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f4eab4c323c0; sha256 a6a6dc5f9abdc59993e0f9162d36edf2f54b82543649bd77585ab6cb508aee2f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/39173044. Agents can read the archived copy with the MCP tool read_document.